CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles - PubMed (original) (raw)
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
Dagmar Beier et al. Cancer Res. 2007.
Free article
Abstract
Although glioblastomas show the same histologic phenotype, biological hallmarks such as growth and differentiation properties vary considerably between individual cases. To investigate whether different subtypes of glioblastomas might originate from different cells of origin, we cultured tumor cells from 22 glioblastomas under medium conditions favoring the growth of neural and cancer stem cells (CSC). Secondary glioblastoma (n = 7)-derived cells did not show any growth in the medium used, suggesting the absence of neural stem cell-like tumor cells. In contrast, 11/15 primary glioblastomas contained a significant CD133(+) subpopulation that displayed neurosphere-like, nonadherent growth and asymmetrical cell divisions yielding cells expressing markers characteristic for all three neural lineages. Four of 15 cell lines derived from primary glioblastomas grew adherently in vitro and were driven by CD133(-) tumor cells that fulfilled stem cell criteria. Both subtypes were similarly tumorigenic in nude mice in vivo. Clinically, CD133(-) glioblastomas were characterized by a lower proliferation index, whereas glial fibrillary acidic protein staining was similar. GeneArray analysis revealed 117 genes to be differentially expressed by these two subtypes. Together, our data provide first evidence that CD133(+) CSC maintain only a subset of primary glioblastomas. The remainder stems from previously unknown CD133(-) tumor cells with apparent stem cell-like properties but distinct molecular profiles and growth characteristics in vitro and in vivo.
Similar articles
- Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F, Sasdelli F, Manini I, Gambarana C, Oliveri G, Miracco C, Sorrentino V. Gambelli F, et al. Cell Biol Int. 2012 Jan;36(1):29-38. doi: 10.1042/CBI20110013. Cell Biol Int. 2012. PMID: 21916848 - Heterogeneous phenotype of human glioblastoma: in vitro study.
Denysenko T, Gennero L, Juenemann C, Morra I, Masperi P, Ceroni V, Pragliola A, Ponzetto A, Melcarne A. Denysenko T, et al. Cell Biochem Funct. 2014 Mar;32(2):164-76. doi: 10.1002/cbf.2988. Epub 2013 Jul 8. Cell Biochem Funct. 2014. PMID: 23836332 - CD133 is essential for glioblastoma stem cell maintenance.
Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G. Brescia P, et al. Stem Cells. 2013 May;31(5):857-69. doi: 10.1002/stem.1317. Stem Cells. 2013. PMID: 23307586 - CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W, Nagasawa DT, Trang A, Thill K, Spasic M, Yang I. Choy W, et al. Neurosurg Clin N Am. 2012 Jul;23(3):391-405. doi: 10.1016/j.nec.2012.04.011. Epub 2012 Jun 5. Neurosurg Clin N Am. 2012. PMID: 22748652 Review. - Glioblastoma and stem cells.
Altaner C. Altaner C. Neoplasma. 2008;55(5):369-74. Neoplasma. 2008. PMID: 18665745 Review.
Cited by
- Global research landscape and trends of cancer stem cells from 1997 to 2023: A bibliometric analysis.
Chen Y, Qu B, Zheng K, Liu Y, Lu L, Zhang X. Chen Y, et al. Medicine (Baltimore). 2024 May 17;103(20):e38125. doi: 10.1097/MD.0000000000038125. Medicine (Baltimore). 2024. PMID: 38758889 Free PMC article. - Cancer Stem Cells from Definition to Detection and Targeted Drugs.
Ruszkowska-Ciastek B, Kwiatkowska K, Marques-da-Silva D, Lagoa R. Ruszkowska-Ciastek B, et al. Int J Mol Sci. 2024 Mar 31;25(7):3903. doi: 10.3390/ijms25073903. Int J Mol Sci. 2024. PMID: 38612718 Free PMC article. Review. - The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
de la Nava D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, Lacalle A, Casares N, Zalacain M, Marrodan L, García-Moure M, Ochoa MC, Tallon-Cobos AC, Hernandez-Osuna R, Marco-Sanz J, Dhandapani L, Hervás-Corpión I, Becher OJ, Nazarian J, Mueller S, Phoenix TN, van der Lugt J, Hernaez M, Guruceaga E, Koschmann C, Venneti S, Allen JE, Dun MD, Fueyo J, Gomez-Manzano C, Gallego Perez-Larraya J, Patiño-García A, Labiano S, Alonso MM. de la Nava D, et al. Neuro Oncol. 2024 Aug 5;26(8):1509-1525. doi: 10.1093/neuonc/noae066. Neuro Oncol. 2024. PMID: 38554031 Free PMC article. - Emerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease.
Pleskač P, Fargeas CA, Veselska R, Corbeil D, Skoda J. Pleskač P, et al. Cell Mol Biol Lett. 2024 Mar 26;29(1):41. doi: 10.1186/s11658-024-00554-0. Cell Mol Biol Lett. 2024. PMID: 38532366 Free PMC article. Review. - Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics.
BharathwajChetty B, Sajeev A, Vishwa R, Aswani BS, Alqahtani MS, Abbas M, Kunnumakkara AB. BharathwajChetty B, et al. Cancer Metastasis Rev. 2024 Mar;43(1):321-362. doi: 10.1007/s10555-024-10171-0. Epub 2024 Mar 22. Cancer Metastasis Rev. 2024. PMID: 38517618 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials